Use of the oral @entity413 tolerance test to define remission in XXXX .

@entity1 @entity442 @entity2124 @entity2012 @entity413
An oral @entity413 tolerance test (OGTT) was used to assess @entity2124 ( @entity2124 ) secretion in @entity1 with @entity2012 prior to (n = 26) and after (n = 71) transsphenoidal adenomectomy as well as in 196 controls. In controls, suppressed concentrations of @entity2124 showed a negative relationship both with body mass index (BMI) and with age. Having calculated the reference intervals for suppressed @entity2124 concentrations to be expected for any given age and BMI, we compared these individually predicted ranges to @entity2124 concentrations actually observed in @entity1 with @entity2012 during OGTT. Preoperatively, concentrations exceeded the normal range in all @entity1 . Postoperatively, @entity413 -suppressed concentrations of @entity2124 were less than 2.0 ng/mL in 56 (79%) @entity1 and less than 1.0 ng/mL in 44 (62%). However, only 37 of 71 (52%) @entity1 had @entity413 -suppressed @entity2124 concentrations within the calculated reference intervals (defined by the 95th percentile of normal). Comparing these data with the @entity1 's concentrations of @entity442 ( @entity442 ; normal range first established and corrected for age and sex in 494 healthy individuals), congruency of both parameters was found in 59 (77%) @entity1 with an unexplained discrepancy between @entity2124 and @entity442 in the remaining in 16 (23%) @entity1 . Our results confirm that concentrations of @entity442 must be corrected for sex and age, whereas @entity413 -suppressed concentrations of @entity2124 depend on age and BMI. "Across-the-board" cut-off-values are clearly inadequate and should not be used. Rather, serum @entity2124 measurements obtained during an OGTT must be interpreted individually by comparison to control values taking into account both age and BMI.
